On November 17, Natera rose 4.69% in Pre-Market Trading, trading at $302.0 per share, with turnover of $0.6391 million.
The move follows renewed attention on the company’s clinical collaboration with Incyte for an interventional phase 2 colorectal cancer study, where Signatera is being used as primary and secondary endpoints and is also planned to help guide enrollment, reinforcing its oncology utility.
Supporting context includes third-quarter revenue of $794.0 million, above market expectations, and raised full-year revenue guidance to $3.005 billion to $3.035 billion. However, the company also reported EPS of $(0.42), worse than consensus, while a resale filing covering up to 68,023 shares and recent director share sales had previously weighed on the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments